Literature DB >> 8725105

Coxsackievirus B3 clinical isolates and murine myocarditis.

C J Gauntt1, M A Pallansch.   

Abstract

Fifteen clinical coxsackievirus B3 (CVB3) isolates were assessed for cardiopathologic capabilities in adolescent male CD-1 mice in comparison to two well characterized cardiovirulent CVB3 strains. One isolate was cardiovirulent, one minimally cardiovirulent and the remaining 13 isolates were noncardiovirulent. The two cardiovirulent isolates and one well characterized cardiovirulent strain, established higher viremic titers, in comparison to five noncardiovirulent isolates that were examined. The two cardiovirulent isolates and one well characterized cardiovirulent strain replicated to significantly higher titers than five noncardiovirulent isolates in primary cultures of murine neonatal or adolescent cardiac fibroblasts. Nucleotide sequence analysis of an area defined by nucleotides(N)300-N599 in the 5'-nontranslated region were performed on the two well characterized cardiovirulent CVB3 strains, the two cardiovirulent isolates and 12 noncardiovirulent isolates. The data detected a single discriminatory nucleotide position. An A was present at N565 in three of four cardiovirulent CVB3, whereas a U or C was present in this position in 12 of 12 noncardiovirulent CVB3. In toto, these data are compatible with the hypothesis that the type of the nucleotide at N565, a position within the internal ribosome entry site, is associated with capacity of a CVB3 for replication in vivo and in vitro and this capacity for vigorous replication is associated with cardiovirulence.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725105     DOI: 10.1016/0168-1702(95)01250-8

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  6 in total

1.  Nitric oxide inhibition of coxsackievirus replication in vitro.

Authors:  C Zaragoza; C J Ocampo; M Saura; A McMillan; C J Lowenstein
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

Review 2.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  Genomic determinants of cardiovirulence in coxsackievirus B3 clinical isolates: localization to the 5' nontranslated region.

Authors:  J J Dunn; N M Chapman; S Tracy; J R Romero
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site.

Authors:  Ji Yuan; David A Stein; Travis Lim; Dexin Qiu; Shaun Coughlin; Zhen Liu; Yinjing Wang; Robert Blouch; Hong M Moulton; Patrick L Iversen; Decheng Yang
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

Review 5.  Myocarditis.

Authors:  Leslie T Cooper
Journal:  N Engl J Med       Date:  2009-04-09       Impact factor: 91.245

6.  Characterization of enterovirus isolates from patients with heart muscle disease in a selenium-deficient area of China.

Authors:  T Peng; Y Li; Y Yang; C Niu; P Morgan-Capner; L C Archard; H Zhang
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.